MENU
Aim higher

PREVIN

A non-invasive treatment to protect visual function in early stage diabetic retinopathy patients

PREVIN combines a novel drug delivery method to treat patients with Diabetic Retinopathy (DR) (i.e. blindness in Diabetes patients) with established drugs. This method will improve localized drug delivery with cyclodextrin nanoparticles to the back of the eye for effective, safe, low-cost, preventive and non-invasive treatment of DR. PREVIN, supported by extensive safety and efficacy studies, will be ready for licensing within one year after the end of the project.
Acronym: 
PREVIN
Project ID: 
11 008
Ranking: 
6
Cut-off: 
6
Start date: 
01-04-2017
Project Duration: 
36months
Project costs: 
2 143 090.00€
Technological Area: 
Pharmaceutical Products / Drugs
Market Area: 
Therapeutic